| Autor: |
Hui D; Department of Palliative Care, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maddocks M; Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College London, London, London, UK., Johnson MJ; Wolfson Palliative Care Research Centre, University of Hull, Hull, UK., Ekström M; Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund University, Lund, Sweden., Simon ST; Department of Palliative Medicine and Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Ogliari AC; Pulmonary Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Booth S; Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College London, London, London, UK; Cambridge Breathlessness Intervention Service, Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, UK., Ripamonti C; Oncology-Supportive Care in Cancer Unit, Department Onco-Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy. |
| Abstrakt: |
Competing Interests: Competing interests: DH has reported research grants from National Cancer Institute (US), National Institute of Nursing Research (US), American Cancer Society, Helsinn, Insys, Teva and Depomed. MM has reported research grants from National Institute for Health Research and consultancy fees from Helsinn and Fresenius Kabi. MJ has received institutional payments for clinical consultancy to Mayne Pharma and honoraria from Novartis. ME has reported honoraria from AstraZeneca, Boehringer Ingelheim, Novartis and Roche. SS has reported research grants from Federal Ministry of Education and Research in Germany and from the European Commission. CR has received funding from InPharm, Kyowa Kirin, Amgen Europe and Molteni SpA. ACO and SB have declared no potential conflicts of interest. |
